Effects of Phototherapy by Low-level Light-emitting Diode Therapy (LEDT) on Clinical, Biochemical, Biomechanical, Histologic and Genetic Responses of Muscle Performance of Young Males Submitted to Physical Strength Training

September 19, 2014 updated by: Cleber Ferraresi, Universidade Federal de Sao Carlos
Muscle performance is largely influenced by modulations in gene expressions of muscle tissue. In this context, light-emitting diode therapy (LEDT) has been used to improve muscle performance in experimental models and human researches. Thereby, the investigators examined modulations in gene expression of muscle tissue as well as biochemical, biomechanic and histologic adaptations influenced by exercise associated to LEDT.

Study Overview

Detailed Description

This study assessed muscle performance in isokinetic dynamometry and led press device, gene expression by RT-PCR, lactate, creatine kinase and morphology of muscle tissue by immunohistochemical analysis

Study Type

Interventional

Enrollment (Actual)

32

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • São Paulo
      • São Carlos, São Paulo, Brazil, 13565-905
        • Federal University of São Carlos

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 28 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • healthy males aged between 18 and 28 years with a body mass index (BMI) equal to or less than 26 kg/m2,
  • moderated pattern of physical activity

Exclusion Criteria:

  • previous injury to the femoral quadriceps or hamstring muscles (within 6 months prior to study),
  • osseous or articular disorder in the lower limbs,
  • cardiovascular system disorders,
  • systemic disease, and
  • taking prescription medicines or using dietary supplements such as muscle mass builders.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Effective light-emitting diode therapy and training
Effects of effective light-emitting diode therapy therapy on muscle performance of young males submitted to physical strength training
Other Names:
  • LED
  • LED therapy
  • Light-emitting diode therapy
Placebo Comparator: Placebo light-emitting diode therapy and training
Effects of placebo light-emitting diode therapy on muscle performance of young males submitted to physical strength training
Other Names:
  • LED
  • LED therapy
  • Light-emitting diode therapy

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Modulations on muscle gene expression by RT-PCR
Time Frame: 12 weeks
12 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Muscle performance in leg press device
Time Frame: 12 weeks
12 weeks
Muscle performance in leg extension device
Time Frame: 12 weeks
12 weeks
Muscle performance in isokinetic dynamometer
Time Frame: 12 weeks
12 weeks
Gene expression
Time Frame: 12 weeks
Gene expression of muscle tissue by RT-PCR
12 weeks

Other Outcome Measures

Outcome Measure
Measure Description
Time Frame
Immunohistochemical analysis
Time Frame: 12 weeks
Immunohistochemical analysis to quantify morphology and cells of muscle tissue as satellite cells.
12 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Cleber Ferraresi, MSc, Universidade Federal de Sao Carlos
  • Study Director: Nivaldo A Parizotto, PhD, Universidade Federal de Sao Carlos
  • Study Director: Vanderlei S Bagnato, PhD, University of São Paulo

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

May 1, 2012

Primary Completion (Actual)

July 1, 2012

Study Completion (Actual)

September 1, 2014

Study Registration Dates

First Submitted

September 15, 2012

First Submitted That Met QC Criteria

January 15, 2013

First Posted (Estimate)

January 18, 2013

Study Record Updates

Last Update Posted (Estimate)

September 23, 2014

Last Update Submitted That Met QC Criteria

September 19, 2014

Last Verified

September 1, 2014

More Information

Terms related to this study

Other Study ID Numbers

  • CAAE: 0326.0.135.000-11

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Healthy

Clinical Trials on Effective light-emitting diode therapy

3
Subscribe